Skip to main content

Advertisement

Log in

In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

In postmenopausal osteoporotic women and up to 3 years of treatment with strontium ranelate, strontium was present only in recently deposited bone tissue resulting from formation activity during the period of treatment. Strontium was shown to be dose-dependently deposited into this newly formed bone with preservation of the mineralization.

Introduction

Interactions between strontium (Sr) and bone mineral and its effects on mineralization were investigated in women treated with strontium ranelate.

Methods

Bone biopsies from osteoporotic women were obtained over 5-year strontium ranelate treatment from phases II and III studies. Bone samples obtained over 3-year treatment were investigated by X-ray microanalysis for bone Sr uptake and focal distribution, and by quantitative microradiography for degree of mineralization. On some samples, Sr distribution (X-ray cartography) was analyzed on whole sample surfaces and the percentage of bone surface containing Sr was calculated. Bone Sr content was chemically measured on whole samples.

Results

In treated women, Sr was exclusively present in bone formed during treatment; Sr deposition depended on the dose with higher focal content in new bone structural units than in old ones constantly devoid of Sr, even after 3-year treatment. A plateau in global bone Sr content was reached after 3 years of treatment. Cartography illustrated the extent of surfaces containing Sr, and formation activity during strontium ranelate treatment was higher in cancellous than in cortical bone. Mineralization was maintained during treatment.

Conclusion

The quality of bone mineral was preserved after treatment with strontium ranelate, supporting the safety of this agent at the bone tissue level.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis—a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060–2066

    Article  CAS  PubMed  Google Scholar 

  2. Meunier PJ, Roux C, Seemar E, Ortolani S, Badurski JE, Spector TM, Cannata J, Balogh A, Lemmel EM, Pors Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468

    Article  CAS  PubMed  Google Scholar 

  3. Reginster JY, Seeman E, De Vernejoul C, Adami S, Compston J, Phenekos C, Devogelaer JP, Diaz Curiel M, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822

    Article  CAS  PubMed  Google Scholar 

  4. Barbara A, Delannoy P, Denis BG, Marie PJ (2004) Normal matrix mineralization induced by strontium ranelate in MC3T3–E1 osteogenic cells. Metabolism 53:532–537

    Article  CAS  PubMed  Google Scholar 

  5. Baron R, Tsouderos Y (2002) In vitro effects of S12911–2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 450:11–17

    Article  CAS  PubMed  Google Scholar 

  6. Bonnelye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42:129–138

    Article  CAS  PubMed  Google Scholar 

  7. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ (1996) The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517–523

    Article  CAS  PubMed  Google Scholar 

  8. Marie PJ, Hott M, Modrowski D, De PC, Guillemain J, Deloffre P, Tsouderos Y (1993) An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8:607–615

    Article  CAS  PubMed  Google Scholar 

  9. Takahashi N, Sasaki T, Tsouderos Y, Suda T (2003) S12911–2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18:1082–1087

    Article  CAS  PubMed  Google Scholar 

  10. Zhu LL, Zaidi S, Peng Y, Zhou H, Moonga BS, Blesius A, Dupin-Roger I, Zaidi M, Sun L (2007) Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem Biophys Res Commun 355:307–311

    Article  CAS  PubMed  Google Scholar 

  11. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R (2004) Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19:2012–2020

    Article  CAS  PubMed  Google Scholar 

  12. Ammann P, Badoud I, Barraud S, Dayer R, Rizzoli R (2007) Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 22:1419–1425

    Article  CAS  PubMed  Google Scholar 

  13. Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P (2008) Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int doi:10.1007/s00198-008-0815-8.

  14. Marie PJ (2003) Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. Osteoporos Int 14:S9–S12

    CAS  PubMed  Google Scholar 

  15. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y, Allain P, Tsouderos Y, Meunier PJ (1996) Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S12911) administration. J Bone Miner Res 11:1302–1311

    Article  CAS  PubMed  Google Scholar 

  16. Cazalbou S, Combes C, Rey C (2002) S12911 treatment maintains bone mineral crystal characteristics. J Bone Miner Res 17:S376–S377

    Google Scholar 

  17. Farlay D, Boivin G, Panczer G, Lalande A, Meunier PJ (2005) Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degrees of mineralisation of bone. J Bone Miner Res 20:1569–1578

    Article  CAS  PubMed  Google Scholar 

  18. LeGeros RZ, Lin S, LeGeros JP, Cazalbou S, Combes C, Dupin Roger I, Rey C (2004) Strontium ranelate treatment preserves bone crystal characteristics and bone mineral reactivity. Osteoporos Int 15:S116–S117

    Google Scholar 

  19. Boivin G, Meunier PJ (2002) Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 43:535–537

    CAS  PubMed  Google Scholar 

  20. Boivin G, Meunier PJ (2002) Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact 2:538–543

    CAS  PubMed  Google Scholar 

  21. Boivin G, Meunier PJ (2002) The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 70:503–511

    Article  CAS  PubMed  Google Scholar 

  22. Boivin G, Meunier PJ (2003) The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporos Int 14:S19–S24

    Article  PubMed  Google Scholar 

  23. Boivin G, Meunier PJ (2003) Methodological considerations in measurement of bone mineral content. Osteoporos Int 14 (Suppl 5):S22–S27

    Article  PubMed  Google Scholar 

  24. Boivin G, Bala Y, Doublier A, Farlay D, Ste-Marie LG, Meunier PJ, Delmas PD (2008) The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients. Bone 43:532–538

    Article  CAS  PubMed  Google Scholar 

  25. Meunier PJ, Boivin G (1997) Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone 21:373–377

    Article  CAS  PubMed  Google Scholar 

  26. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244–1253

    Article  CAS  PubMed  Google Scholar 

  27. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156

    Article  CAS  PubMed  Google Scholar 

  28. Boivin G, Lips P, Ott SM, Harper KD, Sarkar S, Pinette KV, Meunier PJ (2003) Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 88:4199–4205

    Article  CAS  PubMed  Google Scholar 

  29. Boivin G, Vedi S, Purdie DW, Compston JE, Meunier PJ (2005) Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women. Bone 36:562–567

    Article  CAS  PubMed  Google Scholar 

  30. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687–694

    Article  CAS  PubMed  Google Scholar 

  31. Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP, Delmas PD, Meunier PJ (2008) Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23:215–222

    Article  CAS  PubMed  Google Scholar 

  32. Boivin G, Meunier PJ (1993) Histomorphometric methods applied to bone. In: Grupe G, Garland AN (eds) Histology of ancient human bone. Springer, Berlin, pp 137–156

    Google Scholar 

  33. Basle MF, Mauras Y, Audran M, Clochon P, Rebel A, Allain P (1990) Concentration of bone elements in osteoporosis. J Bone Miner Res 5:41–47

    Article  CAS  PubMed  Google Scholar 

  34. Pors Nielsen S (2004) The biological role of strontium. Bone 35:583–588

    Article  CAS  PubMed  Google Scholar 

  35. Staub JF, Foos E, Courtin B, Jochemsen R, Perault Staub AM (2003) A nonlinear compartmental model of Sr metabolism. II. Its physiological relevance for Ca metabolism. Am J Physiol Regul Integr Comp Physiol 284:R835–R852

    CAS  PubMed  Google Scholar 

  36. Staub JF, Foos E, Courtin B, Jochemsen R, Perault Staub AM (2003) A nonlinear compartmental model of Sr metabolism. I. Non-steady-state kinetics and model building. Am J Physiol Regul Integr Comp Physiol 284:R819–R834

    CAS  PubMed  Google Scholar 

  37. Dahl SG, Allain P, Marie PJ, Mauras Y, Boivin G, Ammann P, Tsouderos Y, Delmas PD, Christiansen C (2001) Incorporation and distribution of strontium in bone. Bone 28:446–453

    Article  CAS  PubMed  Google Scholar 

  38. Marie PJ, Ammann P, Boivin G, Rey C (2001) Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121–129

    Article  CAS  PubMed  Google Scholar 

  39. LeGeros RZ, Lin S, Mijares D, LeGeros JP (2003) Strontium ranelate treatment preserves bone crystal characteristics and dissolution properties of bone apatite. J Bone Miner Res 18 (Suppl 2):276

    Google Scholar 

  40. Parfitt AM (2002) Misconceptions (2): turnover is always higher in cancellous than in cortical bone. Bone 30:807–809

    Article  CAS  PubMed  Google Scholar 

  41. Boivin G, Meunier PJ (2004) Inter-individual heterogeneity index of mineralization is an important determinant of the quality of bone. J Bone Miner Res 19 (suppl 1):S114

    Google Scholar 

Download references

Acknowledgments

Present studies were supported by unrestricted research grants from the Institut de Recherches Internationales Servier (Courbevoie, France) and by Institut National de la Santé et de la Recherche Médicale. The expert technical assistance of Catherine Simi, Annie Buffet (Institut National de la Santé et de la Recherche Médicale, INSERM Unité 831, Université de Lyon, France), and Albert Perrat (Centre Technologique des Microstructures, Université de Lyon, Villeurbanne, France) were also gratefully appreciated. The authors also thank Prof. Mark Forwood (Brisbane) for helpful discussions and remarks during the preparation of the manuscript.

Conflicts of interest

The authors have received an unrestricted grant from Institut de Recherches Internationales Servier. They have no further potential conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G. Boivin.

Additional information

Pierre Delmas died on the 23 July 2008

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boivin, G., Farlay, D., Khebbab, M.T. et al. In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos Int 21, 667–677 (2010). https://doi.org/10.1007/s00198-009-1005-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-009-1005-z

Keywords

Navigation